Blood, 2022-10, Vol.140 (16), p.1822-1826
- Soumerai, Jacob D.
- Rosenthal, Allison
- Harkins, Shannon
- Duffy, Jessica
- Mecca, Carmen
- Wang, Yingbing
- Grewal, Ravinder K.
- El-Jawahri, Areej R.
- Liu, Huiyun
- Menard, Cedric
- Dogan, Ahmet
- Yang, Lei
- Rimsza, Lisa M.
- Bantilan, Kurt
- Martin, Haley
- Lei, Matthew
- Mohr, Sydney
- Kurilovich, Anna
- Kudryashova, Olga
- Postovalova, Ekaterina
- Nardi, Valentina
- Abramson, Jeremy S.
- Chiarle, Roberto
- Zelenetz, Andrew D.
- Louissaint, Abner
2022
Details
- Autor(en) / Beteiligte
- Soumerai, Jacob D.
- Rosenthal, Allison
- Harkins, Shannon
- Duffy, Jessica
- Mecca, Carmen
- Wang, Yingbing
- Grewal, Ravinder K.
- El-Jawahri, Areej R.
- Liu, Huiyun
- Menard, Cedric
- Dogan, Ahmet
- Yang, Lei
- Rimsza, Lisa M.
- Bantilan, Kurt
- Martin, Haley
- Lei, Matthew
- Mohr, Sydney
- Kurilovich, Anna
- Kudryashova, Olga
- Postovalova, Ekaterina
- Nardi, Valentina
- Abramson, Jeremy S.
- Chiarle, Roberto
- Zelenetz, Andrew D.
- Louissaint, Abner
- Titel
- Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma
- Ist Teil von
- Blood, 2022-10, Vol.140 (16), p.1822-1826
- Ort / Verlag
- United States: Elsevier Inc
- Erscheinungsjahr
- 2022
- Link zum Volltext
- Quelle
- MEDLINE
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0006-4971eISSN: 1528-0020DOI: 10.1182/blood.2022015443Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9837428